Lupus Science and Medicine Podcast
The Lupus Science & Medicine® podcast is your premier source for the latest insights and developments in lupus and related diseases. Each episode features in-depth interviews with authors and leading experts, covering the newest advances in lupus research and treatments. Lupus Science & Medicine® - lupus.bmj.com - is an esteemed international journal from the BMJ Group and the Lupus Foundation of America (LFA). The journal publishes basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. Subscribe now or listen on your favourite podcast platform to enhance your understanding of lupus. Podcast hosted by: Dr. Anna Wolska, The Lupus Foundation of America, USA
Episodes
Lupus nephritis, affecting nearly half of lupus patients, can cause severe kidney damage. Traditionally, high-dose glucocorticoids (~1 mg per kg prednisone) have been used despite significant side effects. In this episode, host Anna Wolska speaks with Dr. Amit Saxena, a rheumatologist and Associate Professor at NYU Langone Health, about his recent research on the use of glucocorticoids in treating kidney disease in lupus. His study...
Join Dr. Anna Wolska from the Lupus Foundation of America as she talks with Dr. Jim Oates about his recently published study in Lupus Science & Medicine on validating claims-based algorithms in Medicare data to identify SLE and lupus nephritis. Dr. Oates explains how ICD-10 coding and geospatial analysis (via the Lupus Index) can help pinpoint disparities, guide clinical trial recruitment, and reveal how location affects patien...
Early reduction in proteinuria is a key predictor of improved long-term kidney health in lupus nephritis (LN). In this episode, Dr. Anna Wolska from the Lupus Foundation of America speaks with Drs. Maria Dall'Era and Anca Askanase about a new propensity analysis comparing voclosporin-based triple immunosuppressive therapy to traditional high-dose glucocorticoid regimens. They discuss findings from the AURA-LV and AURORA 1 studies, ...
Join Dr. Anna Wolska and Dr. Jordan Roberts, a pediatric rheumatologist, as they explore the use of Rituximab in treating childhood-onset systemic lupus erythematosus (SLE). They discuss key factors for healthcare providers when prescribing Rituximab to children and adolescents, especially for severe cases like lupus nephritis and CNS involvement. Dr. Roberts presents recent research on Rituximab’s safety, highlighting increased in...
In this episode of the Lupus Science and Medicine podcast, Dr. Megan Clowse, a rheumatologist at Duke University, discusses her research on contraceptive practices in women with lupus. Drawing from the RISE Registry, Dr. Clowse explores the alignment of contraception use with 2020 ACR guidelines, uncovering gaps in documentation and prescription practices. The conversation highlights the importance of reproductive health planning, ...
Join host Dr. Anna Wolska as she explores a new study in Lupus Science & Medicine on how positive psychosocial factors—such as resilience, self-efficacy, and emotional support—can reduce stress in people with systemic lupus erythematosus (SLE). In this episode, she speaks with Drs. Kimberly DeQuattro and Sarah Patterson about these factors' protective effects, even for those with trauma histories, and discusses the study's impl...
Join Dr. Anna Wloska from the Lupus foundation of America and Drs. Peter Lipsky and Amerie Grammer as they discuss the effectivenss of krill oil in reducing disease activity in systemic lupus erythematosus. In this episode, our guest highlight the potential therapeutic benefits of restoring omega-3 fatty acids in patients with SLE and the potency and efficacy of omegga-3s found in krill oil versus other sources.
Join Dr. Anna Wolska from the Lupus Foundation of America and Dr. Laurent Arnaud, Professor of Rheumatology at the Department of Rheumatology, University Hospitals of Strasbourg as they discuss systemic lupus erythematosus (SLE) clinical trials. In this episode, Dr. Arnaud highlights the complexities of drug approval processes in lupus, the pivotal role of large-scale phase three randomized trials and critical outcome measures in t...
Join Dr. Anna Wolska from the Lupus Foundation of America as she delves into a groundbreaking discussion with Dr. Stephen Balevic focused on hydroxychloroquine blood levels and understanding medication adherence in lupus patients. In this episode, Dr. Balevic, a rheumatologist and clinical pharmacologist from Duke University, explains the nuances of interpreting hydroxychloroquine levels, the challenges of ensuring patient adherenc...
Join Dr. Anna Wolska and Dr. May Choi as they explore the role of Artificial Intelligence (AI) and Machine Learning (ML) in guiding diagnostic and care decisions for systemic lupus erythematosus (SLE). Dr. Choi delves into key elements of machine learning and its potential impact on improving outcomes, particularly in underserved populations. She also discusses various types of machine learning, such as deep learning, supervised le...
Join Dr. Anna Wolska and Dr. Jim Posada as they delve into the intricacies of RNAse therapy in the management of Systemic Lupus Erythematosus (SLE). In this podcast episode, Dr. Posada describes the groundbreaking study evaluating the efficacy of RSLV-132, a novel RNAse molecule fused to human IgG1 Fc, in reducing chronic inflammation associated with cutaneous lupus. Key findings from the clinical trial reveal that patients with mo...
Dr. Anna Wolska engages in a conversation with Dr. Shivani Garg and Dr. Christie Bartels to delve into the development and implementation of HCQ-SAFE. This innovative decision-aid is designed to empower individuals living with lupus to engage in shared-decision making. The authors discuss the importance of streamlining and enhancing shared decision-making dynamics between patients and healthcare providers regarding the utilization ...
Dr. Anna Wolska speaks to Dr. Michael Belmont and Devyn Zaminski to discuss the importance of dual dsDNA testing in order to full understand disease activity. In this study, they made the observation that there is a large amount of discordance in anti-dsDNA antibodies assays. Misinterpretation or errors in anti- dsDNA antibody testing could have negative implications on long term outcomes in people living with SLE.
Dr. Anna Wolska engages in a discussion with renowned experts, Dr. Catharina Lindholm and Dr. David Jayne, to explore findings from the phase II TULIP Lupus Nephritis trial. This in-depth conversation centers on results from a clinical trial where they evaluated the efficacy of intensified anifrolumab treatment in individuals with active lupus nephritis.
Read the article: http://dx.doi.org/10.1136/lupus-2023-000910
Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinici...
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Ana Malvar and Brad Rovin. They discuss using repeat tissue biopsies to understand progression of lupus nephritis over time. They offer conjecture that both immunosuppression as well as mitigation of tissue fibrosis, resulting from inflammatory resolution, are needed in order to preserve kidney function and prevent progression to kidney failure.
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Anca Askanase and Joan Merrill, the developers of the LFA-REAL tool. Together, they discuss the importance of using a tool like LFA-REAL to understand how clinician and patient reported outcomes are essential for understanding efficacy and effectiveness of experimental therapeutics developed to treat people living with lupus.
Read the article: http://dx.doi.org/...
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Amrie Grammer and Dr. Peter Lipsky from AMPEL BioSolutions. Together they describe the molecular endotypes of Type 1 and Type 2 Systemic Lupus Erythematosus. This episode uncovers the distinct molecular profiles of these SLE types and paves the way for personalized treatment approaches based on these classifications.
Link to published paper: https://lupus.bmj.com...
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Ian Bruce, from the University of Manchester in the UK. Dr Bruce discusses the time to onset of clinical response to Anifrolumab in patients with Systemic Lupus Erythematosus. The episode delves into pooled data from two significant Phase III trials, TULIP-1 and TULIP-2, offering listeners a deep understanding of the effectiveness and timeline of Anifrolumab treatm...
Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personali...
Popular Podcasts
The World's Most Dangerous Morning Show, The Breakfast Club, With DJ Envy And Charlamagne Tha God!
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
Welcome to "Decisions, Decisions," the podcast where boundaries are pushed, and conversations get candid! Join your favorite hosts, Mandii B and WeezyWTF, as they dive deep into the world of non-traditional relationships and explore the often-taboo topics surrounding dating, sex, and love. Every Monday, Mandii and Weezy invite you to unlearn the outdated narratives dictated by traditional patriarchal norms. With a blend of humor, vulnerability, and authenticity, they share their personal journeys navigating their 30s, tackling the complexities of modern relationships, and engaging in thought-provoking discussions that challenge societal expectations. From groundbreaking interviews with diverse guests to relatable stories that resonate with your experiences, "Decisions, Decisions" is your go-to source for open dialogue about what it truly means to love and connect in today's world. Get ready to reshape your understanding of relationships and embrace the freedom of authentic connections—tune in and join the conversation!
Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.
ALL THE SMOKE pairs two of the most outspoken and controversial players of their time. Known as fiery, intense competitors during their on-court careers, Matt Barnes and Stephen Jackson are now two of the most widely respected voices by today’s crop of NBA stars. Serving as mentors to numerous players throughout the league and with their hands firmly on the pulse of the game, they have first-hand insight into the minds, lives and pressing issues facing today’s players. Barnes and Jackson, who have played alongside two generations of All-Stars, will dish on the latest news and drama from on and off the court without boundaries.